MOTS-c and Glaucoma: A Mitochondrial Signal With Bigger Implications Than Eye Pressure?

This audio article is from VisualFieldTest.com.

Read the full article here: https://visualfieldtest.com/en/mots-c-and-glaucoma-a-mitochondrial-signal-with-bigger-implications-than-eye-pressure

Test your visual field online: https://visualfieldtest.com

Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support

Excerpt:

MOTS-c and Glaucoma: A Mitochondrial Signal With Bigger Implications Than Eye Pressure? Glaucoma is an optic nerve disease often linked to high eye pressure, but it involves many cellular stress pathways. MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-c) is a tiny peptide made by mitochondria that helps cells cope with stress. Could it influence glaucoma progression or vulnerability beyond just controlling pressure? This article examines the mechanistic links between MOTS-c and glaucoma. We separate established facts from indirect clues and educated speculation. Every big claim is cited to the literature. What MOTS-c Is In 2015, researchers discovered MOTS-c – a 16-amino-acid peptide encoded in mitochondrial DNA (mtDNA) (). It is produced from a short open reading frame in the mitochondrial 12S rRNA gene (). MOTS-c levels rise in response to stress or exercise and decline with age (). Under stress, MOTS-c moves from the mitochondria to the cell nucleus, where it helps activate antioxidant and stress-defense genes (). MOTS-c acts mainly through cellular energy sensors. It boosts the AMP-activated protein kinase (AMPK) pathway by diverting substrates toward AICAR production, mimicking a fasting/exercise signal () (). AMPK is a key regulator of energy balance in cells. When AMPK is activated, it in turn can increase PGC-1α, a master regulator of mitochondrial function (). Thus, MOTS-c indirectly drives cells to make more energy and repair mitochondria. MOTS-c also influences inflammation and oxidative stress. In cell studies, treating stressed cells with MOTS-c increased AMPK and PGC-1α levels and lowered reactive oxygen species (ROS) and inflammatory signals (). Specifically, MOTS-c reduced activation of NF-κB (a protein that drives inflammation) and cut levels of pro-inflammatory cytokines (like TNF-α, IL-1β, IL-6) while boosting anti-inflammatory IL-10 (). It can also activate NRF2 pathways, which turn on antioxidant defenses () (). In simpler terms, MOTS-c is a stress-adaptive hormone made by mitochondria. It helps cells cope with metabolic and oxidative challenges by fueling energy production and calming inflammation () (). It is being studied for benefits in diabetes, neurodegeneration, and aging-related conditions () (). However, its role in eye diseases (especially glaucoma) is not established. Why Glaucoma Might Intersect with MOTS-c Glaucoma damages the optic nerve and kills retinal ganglion cells (RGCs). Classic glaucoma causes are high intraocular pressure (IOP) and aging, but pressure-independent factors also play a major role. Key features of glaucoma biology may interact with what MOTS-c does: Retinal Ganglion Cell Energy Needs: RGCs have high metabolic demand. Their unmyelinated axons use many ATP-driven ion pumps and are packed with mitochondria (). These cells depend heavily on oxidative phosphorylation (OXPHOS) for energy (). If mitochondria falter, RGCs quickly suffer. In principle, MOTS-c’s ability to boost mitochondrial energy production could protect such high-demand neurons. (This is speculative: RGC-specific data on MOTS-c are lacking.) Mitochondrial Dysfunction in Glaucoma: A growing body of evidence implicates mitochondrial failure in glaucoma () (). For instance, glaucoma patients’ eye tissues and blood show signs of damage

Transcript

SPEAKER_00 0:00

MOTE C and Glaucoma, a mitochondrial signal with bigger implications than eye pressure? Glaucoma is an optic nerve disease often linked to high eye pressure, but it involves many cellular stress pathways. MOTE C, mitochondrial open reading frame of the 12 s rRNA type C, is a tiny peptide made by mitochondria that helps cells cope with stress. Could it influence glaucoma progression or vulnerability beyond just controlling pressure? This article examines the mechanistic links between MOTS C and glaucoma. We separate established facts from indirect clues and educated speculation. Every big claim is cited to the literature. What MOTS C is in 2015, researchers discovered MOTS C, a 16-amino acid peptide encoded in mitochondrial DNA, mtDNA. It is produced from a short open reading frame in the mitochondrial 12 sRRNA gene. MOTS C levels rise in response to stress or exercise and decline with age. Under stress, MOTS C moves from the mitochondria to the cell nucleus, where it helps activate antioxidant and stress defense genes. MOTS C acts mainly through cellular energy sensors. It boosts the AMP-activated protein kinase AMPK pathway by diverting substrates toward ICAR production, mimicking a fasting exercise signal. AMPK is a key regulator of energy balance in cells. When AMK is activated, it in turn can increase PGC1 MA, a master regulator of mitochondrial function. Thus, MOUT-C indirectly drives cells to make more energy and repair mitochondria. MOUTS C also influences inflammation and oxidative stress. In cell studies, treating stressed cells with MOUD C increased AMPK and PGC1 levels and lowered reactive oxygen species, ROS, and inflammatory signals. Specifically, MOTS C reduced activation of NFKB, a protein that drives inflammation, and cut levels of pro-inflammatory cytokines like TNFA, IL1B, IL6, while boosting anti-inflammatory IL-10. It can also activate NRF2 pathways, which turn on antioxidant defenses. In simpler terms, MOTS C is a stress adaptive hormone made by mitochondria. It helps cells cope with metabolic and oxidative challenges by fueling energy production and calming inflammation. It is being studied for benefits in diabetes, neurodegeneration, and aging-related conditions. However, its role in eye diseases, especially glaucoma, is not established. Why glaucoma might intersect with MOTS C? Glaucoma damages the optic nerve and kills retinal ganglion cells, RGCs. Classic glaucoma causes our high interocular pressure, IOP, and aging, but pressure-independent factors also play a major role. Key features of glaucoma biology may interact with what MOTS C does. Retinal ganglion cell energy needs. RGCs have high metabolic demand. Their unmyelinated axons use many ATP-driven ion pumps and are packed with mitochondria. These cells depend heavily on oxidative phosphorylation, oxfos, for energy. If mitochondria falter, RGCs quickly suffer. In principle, MOTS C's ability to boost mitochondrial energy production could protect such high-demand neurons. This is speculative. RGC-specific data on MOTS C are lacking. Mitochondrial dysfunction in glaucoma. A growing body of evidence implicates mitochondrial failure in glaucoma. For instance, glaucoma patients' eye tissues and blood show signs of damaged mTNA and reduced respiratory capacity. Mouse and cell models of ocular hypertension reveal mitochondrial decline even before RGCs die. Because MOT C originates in mitochondria and signals their status, one could imagine it playing a role in this dysfunction. For example, if glaucoma stress reduces MOT C production or signaling, RGC stress responses could weaken. Conversely, adding MOT C might compensate by promoting healthier mitochondria via AMK PGC1A. Oxidative stress. Glaucoma involves oxidative damage in both the front eye, trabecular meshwork, affecting IOP, and back eye, optic nerve head. High IOP and aging elevate ROS, harming RGCs. MOT C is known to trigger antioxidant defenses. It activates NRF2 linked gene expression and reduces ROS via AMPKPGC1 pathways. Thus, MOT C could directly counter oxidative stress in eye tissues. This link is hypothetical but plausible. A hypertension or aging-induced rise in MOT C might help cells clear ROS. Neuroinflammation. Microglia and astrocytes become activated in glaucoma, releasing inflammatory cytokines and complement factors that damage RGCs. In fact, inflammation is now recognized as a key early component of glaucomatous neurodegeneration. MOTE C has anti-inflammatory actions in other systems. It represses NFQB and lowers inflammatory cytokines. It also shapes immune cells, e.g., promoting regulatory T cells via mTOR inhibition. By extension, if MOTS C were active in the retina, it might dampen harmful neuroinflammation. Again, this is an inference. No study has tested MOTS C on glial cells or retinal immune factors. Vascular ischemic stress, poor blood flow and fluctuating perfusion can accompany glaucoma, especially normal tension glaucoma NTG. High IOP can compress retinal blood vessels, causing transient ischemia and oxidative bursts. Ischemia itself produces ROS and inflammatory signals. MOTE C might help tissues adapt to ischemia by improving mitochondrial efficiency and reducing ROS, as seen in heart and muscle models. However, whether MOT C is induced by hypoxia or can cross into retinal tissue after systemic release remains unknown. Aging, age is by far the strongest risk factor for glaucoma. With aging, retinal mitochondria become less efficient and antioxidant defenses falter. MOTE C levels normally decline with age. Thus, older individuals have less of this mitochondrial stress messenger, possibly making RGCs more vulnerable. This suggests a pressure-independent decline of protective signals in glaucoma. Inference, a drop in MOT C may partly explain age-related risk, but direct data are missing. Normal tension versus high-pressure glaucoma. In NTG, patients develop classic glaucoma damage without elevated IOP. This hints at metabolic, vascular, or genetic factors at play. A mitochondrial signal like MOTS C could hypothetically be more relevant in NTG, where pressure isn't the sole driver. Conversely, in high-pressure glaucoma, damage might be dominated by mechanical stress and IOP, potentially limiting MOT C's influence. This remains speculative. No data compare MOTC between NTG and other glaucoma types. In summary, many glaucoma dangers, energy failure, oxidative stress, inflammation, align with known actions of MOTC, energy boosting, antioxidant, anti-inflammatory. This suggests a plausible intersection, but it is largely indirect inference. What direct evidence exists so far? None. We found no published experiment directly linking MOT C to glaucoma or retinal ganglion cells. No study has measured MOT-C in the eyes or blood of glaucoma patients, nor treated glaucoma models with MOT-C. The one eye-related result is in retinal pigment epithelial, RPE cells, relevant to macular degeneration. In that cell type, researchers saw that MOT C is present near mitochondria and protects RPE from oxidative stress. While encouraging, RPE are quite different from RGCs and not involved in glaucoma. There is also no direct animal model work. For example, mice with experimental ocular hypertension have not been reported to receive MOT C supplementation or to have altered MOT C expression. Likewise, no cell culture studies have tested MOTS C on neurons or glia from the eye. In short, direct glaucoma-specific evidence is absent. All we have are educated guesses and analogies, what indirect evidence implies. Since direct data are missing, we turn to related fields. Metabolism and stress. Multiple studies in non-ocular models show MOT C enhances stress resilience. For instance, in exercise and diabetes research, MOTS C improved insulin sensitivity and protected tissues under metabolic stress. In a traumatic brain injury model, MOTS C reduced oxidative damage and improved neurological outcomes. These reinforce that MOTS C C is broadly neuroprotective and antioxidant. By analogy, these effects could extend to retinal neurons. Age and senescence. MOTS C also counters aging-related decline. It has been shown to delay cellular senescence and improve survival in aged tissues. Given that aging links glaucoma with optic nerve susceptibility, loss of MOTS C could be one piece of the puzzle. For example, if older retinas fail to produce enough MOTE C under stress, they might lack a vital survival signal. Mitochondrial disease links. Some forms of glaucoma resemble mitochondrial DNA disorders, e.g. Lieber's hereditary optic neuropathy. In fact, shared mtDNA mutations are observed. MOT C belongs to a family of mitochondrial peptides, others include humanin, that showed protective effects in mitochondrial diseases. For example, humanin analogs protect RGCs in some models. This cluster of findings suggests mitochondrial signals matter in eye health. AMPK and CERT1, resveratrol, a CERT 1 activator, was reported to save RGCs in glaucoma models. MOT-C likewise engages CERT1 and AMPK in cells. This mechanistic similarity hints MOT-C might mimic some of resveratrol's benefits for RGCs. However, this is hypothetical. There is no study confirming MOTS C CERT1 interplay in retinal neurons. Taken together, these adjacent findings support the idea that boosting mitochondrial adaptive responses could shield RGCs. They do not prove MOT-C itself is critical in glaucoma, but they make it plausible. We emphasize each step from MOT C's cell signals to glaucoma pathology is supported by analogies, not glaucoma-specific tests. A systems-level hypothesis. We can sketch a conceptual network. Imagine MOT-C as a node in the cell's stress network. Upstream triggers, cellular energy stress, low ATP, high AMP, exercise, calorie restriction, or oxidative damage all stimulate MOTC expression. In glaucoma, factors like hypoxia or higher OS might trigger a MOT-C response, though we don't know if they do in the eye. MOT-C node. When produced, MOT-C moves to the nucleus. It interacts with transcription factors and signaling hubs. It raises AMPK, CERT1, PGC1A activity, and activates NRF2 while inhibiting NFKB and MTORT1. Downstream effects. These changes enhance mitochondrial biogenesis, energy metabolism, and antioxidant defenses, while dialing down inflammation. In the retina, that could translate to better RGC survival, healthier glia, and stabilized blood flow regulation. Feedback loops. AMPK not only is activated by MOT C, but in turn helps shuttle MOT C into the nucleus, creating a positive loop. Aging or continuous stress might weaken this loop, less MOT C is made as cells get older. Where is evidence strong or weak? The fact that MOT C influences AMPGC1H and inflammation in other tissues is well supported. The existence of mitochondrial stress and oxidative damage in glaucoma is strongly documented. The link that MOT C connects these two systems is hypothetical. We have no data on MOT C levels in retina or how glaucoma stimuli affect it. This is the big white box in the network. In short, the model suggests mitochondrial stress, MOT C increase, protective gene activation, RGC resilience. If any step fails, for instance, aging lowering MOT C output, injury can proceed. This is an appealing framework, but it has many gaps. It highlights where to focus experiments, mainly on sensing if and how MOT C operates in eye cells. Counter-arguments and weak points. Several reasons temper enthusiasm. Lack of eye-specific data. All the glaucoma MOTC connections above are inference or analogy. We must not overclaim. It is possible MOTS C does nothing significant in the eye environment. For example, RPE findings don't guarantee anything for RGCs. Delivery and stability. MOTC is a small peptide. Like many peptides, it may be broken down quickly in the body and might not cross tissue barriers easily. There is no data on how long MOTS C circulates or whether it reaches the retina at meaningful levels. Even if injected, it might degrade before helping RGCs. No known pharmacokinetic studies address ocular delivery of MOT C. Systemic versus local, MOT-C acts systemically, e.g., muscle blood liver. Glaucoma is a focal eye disease. It's unclear if systemic MOT C influences the eye directly or if local ocular cells produce and use their own MOT C. If the retina makes little MOT C itself, then relying on circulating MOT C could be ineffective. Glaucoma heterogeneity. Glaucoma patients vary widely, age, blood pressure, genetics. Even if MOT C were beneficial, it might matter for only a subset of cases, perhaps those with metabolic syndrome or normal tension glaucoma. It could be epiphenomenon in other cases where pressure damage dominates. Potential side effects. Boosting a pleotropic signal has unknown effects. The wide action of MOT C, metabolism immunity, means giving it systemically could have off-target impacts. This is a general concern for any drug, but worth noting. Reverse causality. If we found low MOT C in glaucoma patients, is it cause or effect? Glaucoma or treatment might suppress MOT C production rather than MOT C protecting against glaucoma. We must test causality. Rodent versus human. Many MOT C studies are in mice or cell lines. Human glaucoma may differ. For instance, the 16AA MOT C sequence is identical across mammals, but the control of its expression might not be. In summary, while it is tempting to link MOT C and glaucoma via general biology, the lack of direct evidence is a major weakness. It could turn out to be a red herring. What should be tested next? Given the intriguing hints, here are key experiments and studies to do. Measure MOT C in patients. Compare MOT C levels in blood, tear fluid, or aqueous humor from glaucoma patients and healthy controls. Subgroup analyses could check normal tension versus high-pressure glaucoma. If glaucoma patients have chronically lower MOT C, that would motivate deeper study. Cell culture models expose cultured RGC neurons or retina explants to glaucoma-like stress, such as oxidative damage or pressure mimic with and without MOTS C. Does MOTS C reduce cell death, ROS levels, or inflammatory markers? Conversely, does blocking AMPK nephir effector abrogate the benefit? Animal glaucoma models induce ocular hypertension in rats or mice, e.g., microbead occlusion, and administer MOTS C systemically or intravitreally. Then measure RGC survival, optic nerve pathology, and visual function. A well-designed trial would have dose response and timing and possibly use both normal and aged animals. Retinal gene analysis in animals or cell models tests if MOTS C treatment changes expression of key protective genes, AMPK targets, antioxidant genes, mitochondrial biogenesis factors in the retina or optic nerve head. Compare with known glaucoma stress signatures. Genetic models, if available, create mice that lack or overproduce MOTS C, knockout of the mitochondrial ORF or transgenic overexpression, and see if they are more or less prone to glaucoma damage. This is a longer-term idea. Link with other risk factors. Study if metabolic syndrome or diabetes, where MOTS C effects are known, alter glaucoma risk or progression, and whether MOTS C correlates. Each of these would help confirm or refute the hypothesis. They would clarify whether MOTS C is a bystander marker or a functional player. Conclusion. In conclusion, could MOTS C matter in glaucoma? The answer is that we simply don't know yet. There is no direct proof either way. On one hand, MOTS C carries out many functions, AMKPGC1 activation, oxidative stress reduction, inflammation suppression that theoretically align with needs for RGC survival. On the other hand, the evidence is all indirect and derived from other systems. Without targeted studies in I's or glaucoma models, any assertion about MOT C's role is a hypothesis, not a fact. Thus, at present, MOTC is best viewed as a candidate signal that suggests mitochondria and metabolism deserve attention in glaucoma. It might be more useful as a clue pointing researchers toward broader mitochondrial interventions rather than a standalone therapy. Its strongest potential relevance is in pressure-independent normal tension glaucoma or cases with metabolic risk factors, where traditional pressure-lowering treatments do not fully prevent optic nerve loss. But these ideas remain speculative. Crucially, MOT-C might turn out to be an epiphenomenon, something that changes during stress without controlling disease, or it might modestly modify the pace of ganglion cell loss. We cannot yet say if it is harmful, helpful, or neutral in glaucoma. For now, MOT C highlights the systems-level link between mitochondrial health and optic nerve resilience. The assumptions about its effects are biologically plausible but unproven. The bottom line: researchers should not assume MOT-C is a silver bullet for glaucoma. However, it represents an intriguing intersection of metabolic signaling and neurodegeneration that merits careful testing. Claim evidence level, why it may matter. How to test. MOTS C enhances cellular energy and antioxidant defenses. Strong non-ocular, well documented in multiple models. RGCs need lots of ATP and ROS protection. This could bolster their survival under stress. Treat stressed retinal ganglion cell cultures or animal glaucoma models with MOTS C and measure cell survival, ATP levels, and oxidative damage. MOTS C reduces neuroinflammation via NF KGB inhibition. Moderate, indirect, shown in immune TBI models, but not tested in eye. Inflammation drives glaucomatous damage. Suppressing it could protect nerve cells. In vitro, add MOT C to retinal glia or microglia stimulated to be pro-inflammatory and assay cytokine NFKB activity. MOT-C declines with aging and metabolic disease, increasing glaucoma vulnerability. Limited, known to fall with age, and in diabetes models, but unstudied in patients. Aging is a key glaucoma risk factor. Low MOTS C could be one reason older eyes fail to handle stress. Epidemiological study measure MOTC in blood of young versus old subjects and correlate levels with glaucoma presence or severity. Exogenous MOTS C could be a neuroprotective therapy. Speculative, conceptual extension, very little direct testing in neuronal systems. If true, it would add a non-pressure therapy avenue for glaucoma. Interventional animal study. Administer MOT-C analog properly stabilized in a glaucoma model and assess optic nerve damage. MOT C is unlikely to reach retinal neurons effectively. Weak hypothesis. Peptides often have short half-life, ocular delivery barriers exist. If true, systemic MOT-C treatments might not benefit the eye, limiting therapeutic potential. Pharmacokinetic experiment, label MOT C, inject an animal, and measure peptide levels in ocular tissues over time. Circulating MOT C levels may result from disease, not cause it. Speculative, no causal data. If true, low MOT C in patients might just mark glaucoma severity, not drive it. Longitudinal study, track MOT C levels and glaucoma progression over time. Test if baseline MOT C predicts future damage. All links to sources are available in the text version of this article. You can find the full article at VisualFieldTest.com. Thanks for listening. To check your visual field, click the link at the bottom of this article or visit visualfieldtest.com.